Humira vs Dupixent
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Humira | US Dupixent | |
|---|---|---|
| Generic name | adalimumab | dupilumab |
| Drug class | TNF Inhibitor (Biologic) | IL-4/IL-13 Inhibitor (Biologic) |
| Treats | Rheumatoid arthritis, psoriasis, Crohn's disease | Eczema, asthma, nasal polyps |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Sanofi/Regeneron |
| Year approved | 2002 | 2017 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $500M | $390M |
| Common side effects | Serious infections, Increased cancer risk, Allergic reactions, Injection site reactions | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia |
Frequently asked questions
Is Humira or Dupixent better?
Neither is universally "better." Humira (adalimumab) and Dupixent (dupilumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Humira and Dupixent?
Humira is a TNF Inhibitor (Biologic) made by AbbVie, while Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Humira has the larger estimated TV advertising budget of the two.